Sichuan Kelun Pharmaceutical (002422) Stock Overview
Researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
002422 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sichuan Kelun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥32.36 |
| 52 Week High | CN¥41.72 |
| 52 Week Low | CN¥28.14 |
| Beta | -0.12 |
| 1 Month Change | -6.66% |
| 3 Month Change | 1.89% |
| 1 Year Change | -4.51% |
| 3 Year Change | 2.47% |
| 5 Year Change | 47.83% |
| Change since IPO | 116.60% |
Recent News & Updates
Narrative Update • Apr 22
002422: Higher P/E Expectations And Completed Buyback Are Expected To Support Upside
Analysts have raised their price target on Sichuan Kelun Pharmaceutical to CN¥47.0 from CN¥46, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News The company completed a share buyback tranche covering 350,000 shares, equal to 0.02% of outstanding equity, under the program announced on January 5, 2026 (Key Developments).
Narrative Update • Apr 08
002422: Share Buyback And Lower Future P/E Will Sustain Overvaluation Risk
Analysts have kept their CN¥29.0 price target for Sichuan Kelun Pharmaceutical unchanged, citing adjusted assumptions for revenue growth, profit margin and future P/E that they see as balancing each other out. What's in the News Sichuan Kelun Pharmaceutical completed a share repurchase program announced on January 5, 2026, buying back 350,000 shares for CNY 10.37 million, equivalent to 0.02% of its share capital (Key Developments).Recent updates
Narrative Update • Apr 22
002422: Higher P/E Expectations And Completed Buyback Are Expected To Support Upside
Analysts have raised their price target on Sichuan Kelun Pharmaceutical to CN¥47.0 from CN¥46, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News The company completed a share buyback tranche covering 350,000 shares, equal to 0.02% of outstanding equity, under the program announced on January 5, 2026 (Key Developments).Narrative Update • Apr 08
002422: Share Buyback And Lower Future P/E Will Sustain Overvaluation Risk
Analysts have kept their CN¥29.0 price target for Sichuan Kelun Pharmaceutical unchanged, citing adjusted assumptions for revenue growth, profit margin and future P/E that they see as balancing each other out. What's in the News Sichuan Kelun Pharmaceutical completed a share repurchase program announced on January 5, 2026, buying back 350,000 shares for CNY 10.37 million, equivalent to 0.02% of its share capital (Key Developments).Narrative Update • Mar 25
002422: Share Repurchase Plan Will Likely Mask Overvaluation Risk
Analysts have kept their CN¥29.0 price target on Sichuan Kelun Pharmaceutical broadly steady, pointing to slightly higher modeled revenue growth, a small uplift in profit margin and a marginally lower future P/E assumption as reasons to maintain their view. What's in the News Sichuan Kelun Pharmaceutical announced a share repurchase program of up to CN¥100m of class A shares, with a maximum repurchase price of CN¥35 per share, funded by the company's own funds (Key Developments).
Narrative Update • Mar 10
002422: Share Repurchase And New Agreements Will Support Future Returns
Analysts have maintained their CN¥39.00 price target for Sichuan Kelun Pharmaceutical, citing only minor adjustments to long term discount rate, revenue growth, profit margin and future P/E assumptions that do not materially change their view on the stock's valuation. What's in the News Sichuan Kelun Pharmaceutical announced a share repurchase program of up to CNY 100,000,000 of class A shares, with a maximum repurchase price of CNY 35 per share.Narrative Update • Feb 24
002422: Share Repurchase And New Agreements Will Support Balanced Medium Term Outlook
Analysts have revised their price target for Sichuan Kelun Pharmaceutical from CN¥30 to CN¥29, reflecting updated views that incorporate more moderate revenue growth assumptions, slightly higher profit margins, and a small adjustment to the forward P/E and discount rate inputs. What's in the News Sichuan Kelun Pharmaceutical Co., Ltd.Narrative Update • Feb 10
002422: Share Repurchase Plan Will Support Future Returns Despite Softer Margin Outlook
Analysts have slightly lowered their price target on Sichuan Kelun Pharmaceutical to about ¥39.0 from roughly ¥39.83, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that they consider a better reflection of current conditions. What's in the News Sichuan Kelun Pharmaceutical Co., Ltd.Narrative Update • Jan 26
002422: Share Repurchase Plan Will Underpin Future Returns Despite Slight Margin Headwinds
Analysts have lowered their price target on Sichuan Kelun Pharmaceutical to about ¥39.83 from roughly ¥40.31, citing slightly more cautious assumptions on revenue growth and profit margins, along with a modestly higher forward P/E multiple. What's in the News Sichuan Kelun Pharmaceutical has announced a share repurchase program of up to CNY 100,000,000 in class A shares, with a maximum repurchase price of CNY 35 per share.Narrative Update • Jan 11
002422: Overvaluation Will Persist Despite New Supply And R&D Agreements
Analysts have nudged their price target on Sichuan Kelun Pharmaceutical slightly higher to reflect modest adjustments to revenue growth, profit margin and future P/E assumptions, while keeping fair value broadly in line with prior views. What's in the News SSY Group Limited and Sichuan Kelun entered into a Master Research & Development Services Agreement on 23 December 2025, covering R&D services from 1 January 2026 to 31 December 2026.Narrative Update • Dec 27
002422: Fair Value Will Reflect Higher Sales Outlook And Softer Margins
Analysts have trimmed their fair value estimate for Sichuan Kelun Pharmaceutical from CNY 32.38 to CNY 30.00, reflecting slightly lower expected profit margins and valuation multiples, partly offset by higher projected revenue growth. Valuation Changes Fair Value Estimate has fallen slightly from CN¥32.38 to CN¥30.00, implying a modest reduction in the intrinsic valuation.Narrative Update • Dec 13
002422: Interim Dividend Will Support Future Returns Despite Slight Margin Headwinds
Analysts have slightly reduced their price target for Sichuan Kelun Pharmaceutical, citing marginally softer long term revenue growth and profit margin assumptions, partially offset by a modestly higher expected future P E multiple. This has resulted in a fair value adjustment from approximately ¥40.59 to ¥40.31.Narrative Update • Nov 29
002422: Interim Dividend Will Sustain Positive Momentum Despite Modest Earnings Adjustments
Analysts have slightly reduced their price target for Sichuan Kelun Pharmaceutical. They now estimate a fair value of ¥40.59 per share, citing softer projections for revenue growth and profit margins going forward.Narrative Update • Nov 15
002422: Interim Dividend Approval Will Support Profitable Outlook Into 2025
Analysts have slightly lowered their price target for Sichuan Kelun Pharmaceutical from ¥40.92 to ¥40.59. This change is due to more cautious assumptions for revenue growth and discount rates, while maintaining a broadly favorable outlook on profitability and valuation metrics.Narrative Update • Oct 31
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
Analysts have revised their price target for Sichuan Kelun Pharmaceutical, maintaining it at ¥40.92. They anticipate higher revenue growth and improved profit margins, while slightly adjusting future earnings expectations.Narrative Update • Oct 17
Expanding ADC Pipeline Will Unlock Global Oncology Markets
Analysts have maintained their price target for Sichuan Kelun Pharmaceutical at ¥40.92. They cite minimal changes in growth and margin expectations as the basis for their steady outlook.Narrative Update • Oct 03
Expanding ADC Pipeline Will Unlock Global Oncology Markets
Analysts have slightly lowered their price target for Sichuan Kelun Pharmaceutical to ¥40.92 from ¥41.78. This adjustment reflects modestly softer expectations for revenue growth and profit margins in upcoming periods.New Narrative • Aug 24
Expanding ADC Pipeline Will Unlock Global Oncology Markets
Key Takeaways Expanding innovative drug pipeline and commercial launches, underpinned by rapid insurance uptake, drive strong growth in recurrent and high-visibility revenues. International partnerships and broad innovation investments enhance earnings potential, margin expansion, and global market presence.Shareholder Returns
| 002422 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.9% | 0.05% | 4.2% |
| 1Y | -4.5% | 7.4% | 36.2% |
Return vs Industry: 002422 underperformed the CN Pharmaceuticals industry which returned 7.4% over the past year.
Return vs Market: 002422 underperformed the CN Market which returned 36.2% over the past year.
Price Volatility
| 002422 volatility | |
|---|---|
| 002422 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002422 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002422's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 20,127 | Sichuan Liu | www.kelun.com |
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications.
Sichuan Kelun Pharmaceutical Co., Ltd. Fundamentals Summary
| 002422 fundamental statistics | |
|---|---|
| Market cap | CN¥53.28b |
| Earnings (TTM) | CN¥1.57b |
| Revenue (TTM) | CN¥18.38b |
32.8x
P/E Ratio2.8x
P/S RatioIs 002422 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002422 income statement (TTM) | |
|---|---|
| Revenue | CN¥18.38b |
| Cost of Revenue | CN¥9.84b |
| Gross Profit | CN¥8.54b |
| Other Expenses | CN¥6.97b |
| Earnings | CN¥1.57b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 46.45% |
| Net Profit Margin | 8.55% |
| Debt/Equity Ratio | 14.4% |
How did 002422 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield60%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/13 08:39 |
| End of Day Share Price | 2026/05/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sichuan Kelun Pharmaceutical Co., Ltd. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Yinhao Tang | Citic Securities Co., Ltd. |